A Multicenter, Open-label, Uncontrolled Phase II Study to Investigate Efficacy and Safety of ONO4538 in Patients With Rhabdoid Tumor
Latest Information Update: 04 Dec 2024
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Rhabdoid tumour
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 14 Nov 2024 Planned initiation date changed from 30 Sep 2024 to 30 Nov 2024.
- 14 Nov 2024 Status changed from not yet recruiting to recruiting.
- 09 Oct 2024 New trial record